QuidelOrtho Corporation (QDEL)
QDEL trades on Nasdaq in Health Care, Biotechnology: In Vitro & In Vivo Diagnostic Substances. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-28, https://www.sec.gov/Archives/edgar/data/1906324/000190632426000008/0001906324-26-000008-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-28.
Profile
| Field | Value |
|---|---|
| Ticker | QDEL on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001906324 |
| SEC industry code | In Vitro & In Vivo Diagnostic Substances |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $2.7B |
| Net income | -$1.1B |
| Operating income | -$919.2M |
| Net margin | -41.5% |
| Operating margin | -33.7% |
| Revenue growth | -1.9% |
| Cash | $169.8M |
| Total assets | $5.8B |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 0.3× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-04 |
| Cash and burn | $166.4M cash; operating cash flow $2.0M a quarter. | Report 2026-09-27 |
| Shares outstanding | 68,612,588 (2026-10-28); 67,931,540 a year earlier; 66,818,718 three years earlier. | Cover page 2026-10-28 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | KPMG LLP, Short Hills, New Jersey, United States; changed auditors 1 time in 24 months | 8-K 4.01 2025-03-04 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $1.2M, sold $112K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-27 | $618.9M | -$53.8M | $19.6M | $166.4M | $2.9B | $2.6B | 10-Q 2026-11-04 |
| Q2 2026 2026-06-28 | $630.9M | -$92.9M | -$110.6M | $123.4M | $2.9B | $2.7B | 10-Q 2026-08-07 |
| Q1 2026 2026-03-29 | $619.8M | -$91.8M | -$33.0M | $140.4M | $2.7B | $2.7B | 10-Q 2026-05-06 |
| Q4 2025 2025-12-28 | $723.6M | -$130.7M | $131.9M | $169.8M | $2.7B | $2.7B | 10-K 2026-02-19 |
| Q3 2025 2025-09-28 | $699.9M | -$733.0M | -$45.5M | $98.1M | $2.7B | $2.7B | 10-Q 2026-11-04 |
| Q2 2025 2025-06-29 | $613.9M | -$255.4M | -$46.8M | $151.7M | $2.6B | $2.7B | 10-Q 2026-08-07 |
| Q1 2025 2025-03-30 | $692.8M | -$12.7M | $65.6M | $127.1M | $2.5B | $2.8B | 10-Q 2026-05-06 |
| Q4 2024 2024-12-29 | $707.8M | -$178.4M | $63.7M | $98.3M | $2.5B | $2.8B | 10-K 2026-02-19 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2024-11-20 |
| Latest annual report | 10-K | 2026-02-19 |
| Latest quarterly / interim | 10-Q | 2026-11-04 |
| Latest current report | 8-K | 2026-11-03 |
| Latest proxy | DEFA14A | 2026-04-27 |
Source: SEC EDGAR submissions feed, 504 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +0.4% |
| 1 month | -23.8% |
| 3 months | -28.8% |
| Year to date | -62.4% |
| 1 year | -51.6% |
| From 52-week high | -69.6% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: In Vitro & In Vivo Diagnostic Substances
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| QUIT | Achieve Life Sciences Inc. Common Shares | $6.06 | -4.11% | $666.8M |
| NNNN | Anbio Biotechnology | $3.88 | +1.57% | $558.3M |
| MYGN | Myriad Genetics Inc. | $5.57 | -1.59% | $534.3M |
| TKNO | Alpha Teknova Inc. | $7.77 | -5.36% | $488.8M |
| NTLA | Intellia Therapeutics Inc. | $9.86 | +1.65% | $1.4B |
| CLDX | Celldex Therapeutics Inc. | $28.59 | -0.83% | $2.2B |
| NEOG | Neogen Corporation | $10.88 | -3.12% | $2.4B |
| ICCC | ImmuCell Corporation | $11.42 | +6.23% | $103.8M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier